Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
30.06.2025 07:00:05
|
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
BioVersys AG / Key word(s): AGMEGM Ad hoc announcement pursuant to Art. 53 LR
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, today announced the results of the Company’s Annual General Meeting (AGM) of Shareholders held on June 27, 2025.
A total of 55.4% of the Company’s share capital was represented at the meeting.
All items on the agenda received the required majority of votes in favor, including:
Dr. Seng Chin Mah, Chairman of the Board of the Directors commented: “I would like to thank our shareholders for their continued strong support of our strategy as we embark on the final clinical development phase for BV100 with the initiation of Phase 3 later in the year. We will also continue to progress our second clinical asset, alpibectir, as well as our preclinical projects. We remain committed to bringing our novel therapies to patients in dire need and to returning stakeholder value. The Board of Directors and Management would also like to thank Dr. Henni Ropponen for her invaluable contributions during her board tenure and we welcome Dr. Ulrik Schulze to the Board of Directors.”
The minutes and the relevant documents relating to the shareholders’ meeting, including the Annual Report, will be available on the Company’s website under the following links: Annual Report: https://ir.bioversys.com/investor-relations/financials/financial-reports AGM: https://ir.bioversys.com/investor-relations/governance-csr/annual-general-meeting
BioVersys contact End of Inside Information |
2162098 30-Jun-2025 CET/CEST
Nachrichten zu BioVersys
04.07.25 |
Schwacher Handel: SPI beginnt Freitagshandel mit Verlusten (finanzen.ch) | |
02.07.25 |
BioVersys-Aktie gewinnt: BioVersys fliessen dank Forschungsabkommen 5 Millionen Franken zu (AWP) | |
02.07.25 |
Zuversicht in Zürich: SPI präsentiert sich fester (finanzen.ch) | |
02.07.25 |
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE (EQS Group) | |
30.06.25 |
SPI aktuell: SPI zeigt sich mittags leichter (finanzen.ch) | |
30.06.25 |
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS (EQS Group) | |
27.06.25 |
Freundlicher Handel: SPI verbucht zum Handelsende Gewinne (finanzen.ch) | |
27.06.25 |
Gute Stimmung in Zürich: SPI fester (finanzen.ch) |
Im BX Morningcall werden folgende Aktien analysiert und erklärt – heute mit dem monatlichen Rebalancing:
NEU✅ Broadcom Inc
NEU✅ Quanta Services
NEU✅ JPMorgan Chase & Co
inklusive Rebalancing:
❌ Wolters Kluwer
❌ Thales
❌ Waste Connections
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Handelskonflikt im Fokus: SMI moderat im Minus -- DAX geht schwächer ins Wochenende -- Asiens Börsen letztlich uneinheitlichDer heimische Aktienmarkt zeigte sich vor dem Wochenende minimal tiefer. Der deutsche Leitindex gab ebenfalls nach. An der Wall Street ruht der Handel vor diesem Wochenende wegen eines Feiertags. Die Börsen in Fernost tendierten am Freitag in verschiedene Richtungen.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |